Singapore, Aug. 24 -- US-based Charles River Laboratories International, and Medigen Vaccine Biologics Corp. (MVC), headquartered in Taiwan, have collaborated on the characterisation and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine.

Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent enterovirus vaccine.

MVC's proprietary ENVACGEN(R) Enterovirus 71 Vaccine has been approved in Taiwan and Vietnam, demonstrating the company's proven capability to develop and manufacture vaccines that meet international quality standar...